Nampt-IN-3

• UNSPSC Description:

  Nampt-IN-3 (Compound 35) simultaneously inhibit nicotinamide phosphoribosyltransferase (NAMPT) and HDAC with IC50s of 31 nM and 55 nM, respectively. Nampt-IN-3 effectively induces cell apoptosis and autophagy and ultimately leads to cell death[1].

• Target Antigen:

  Apoptosis; Autophagy; HDAC; NAMPT

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/nampt-in-3.html

• Purity:

  98.97

• Solubility:

  DMSO : 130 mg/mL (ultrasonic)

• Smiles:

  O=C(C1=CC=C(C2=CN(CC3=CC=C(C(NC4=CC=CC=C4N)=O)C=C3)N=N2)C=C1)NCC5=CC=CN=C5

• Molecular Weight:

  503.55

• References & Citations:

  [1]Dong G, et al. Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors. J Med Chem. 2017 Oct 12;60(19):7965-7983.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  2121591-52-2